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Abstract
If highly pathogenic H5N1 influenza viruses acquire affinity for human rather than avian respiratory epithelium, will their
susceptibility to neuraminidase (NA) inhibitors (the likely first line of defense against an influenza pandemic) change as well?
Adequate pandemic preparedness requires that this question be answered. We generated and tested 31 recombinants of A/
Vietnam/1203/04 (H5N1) influenza virus carrying single, double, or triple mutations located within or near the receptor
binding site in the hemagglutinin (HA) glycoprotein that alter H5 HA binding affinity or specificity. To gain insight into how
combinations of HA and NA mutations can affect the sensitivity of H5N1 virus to NA inhibitors, we also rescued viruses
carrying the HA changes together with the H274Y NA substitution, which was reported to confer resistance to the NA
inhibitor oseltamivir. Twenty viruses were genetically stable. The triple N158S/Q226L/N248D HA mutation (which eliminates
a glycosylation site at position 158) caused a switch from avian to human receptor specificity. In cultures of differentiated
human airway epithelial (NHBE) cells, which provide an ex vivo model that recapitulates the receptors in the human
respiratory tract, none of the HA-mutant recombinants showed reduced susceptibility to antiviral drugs (oseltamivir or
zanamivir). This finding was consistent with the results of NA enzyme inhibition assay, which appears to predict influenza
virus susceptibility in vivo. Therefore, acquisition of human-like receptor specificity does not affect susceptibility to NA
inhibitors. Sequence analysis of the NA gene alone, rather than analysis of both the NA and HA genes, and phenotypic
assays in NHBE cells are likely to adequately identify drug-resistant H5N1 variants isolated from humans during an outbreak.
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Introduction
The spread of highly pathogenic avian influenza A (H5N1)
viruses from Asia to the Middle East, Europe, and Africa raises
serious concern about a potential human pandemic [1,2]. H5N1
avian influenza virus has been reported in poultry in 63 countries;
359 human cases have been confirmed in 14 countries, with a
mortality rate .60% [3]. A poor fit between avian viruses and
human cellular receptors is thought to be one of the main barriers
to efficient transmission of H5N1 influenza viruses between
humans [2,4–6]. The hemagglutinin (HA) glycoproteins of avian
influenza viruses bind to avian cell-surface receptors whose
saccharides terminate in sialic acid (SA)-a2,3-galactose (SAa2,3-
Gal), whereas those of human influenza viruses bind to human
receptors whose saccharides end in SAa2,6Gal. A change in
receptor specificity from SAa2,3Gal to SAa2,6Gal is thought to
be necessary before avian influenza viruses can cause a pandemic
[4–6].
Neuraminidase (NA) inhibitors (oseltamivir and zanamivir) are
anti-influenza drugs that are likely to be the first line of defense in
the event of an influenza pandemic, before antigenically matched
influenza vaccine is available [1,7–10]. Although HA mutations
that alter viral receptor affinity/specificity can contribute to NA
inhibitor resistance in vitro by allowing efficient virus release from
infected cells without the need for significant NA activity [9,11–
18], the importance of HA mutations in the clinical management
of influenza in humans remains uncertain [11,19–23]. One
important problem is the lack of a reliable experimental approach
(i.e., an appropriate cell-culture–based system) for screening viral
isolates for drug sensitivity [9,11,19,20]. HA mutations can either
increase or mask NA inhibitor resistance in the available assay
systems, which are therefore susceptible to false-positive [24,25]
and false-negative [21,22] results. This problem is likely to reflect a
mismatch between human virus receptors and those in available
cell-culture systems. The human airway epithelial cells targeted by
influenza virus express high concentrations of SAa2,6Gal-
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the continuous cell lines used to propagate influenza viruses
[9,11,19,20,26].
To test whether altered receptor-binding properties of the viral
HA glycoprotein of highly pathogenic A/Vietnam/1203/04
(H5N1) influenza virus can reduce susceptibility to NA inhibitors
in vivo, we generated 31 recombinant viruses carrying amino acid
changes within or near the receptor binding site that alter binding
affinity or specificity [27]. To evaluate the recombinant viruses’
resistance to NA inhibitors, we used, for the first time, a cell-
culture–based system that morphologically and functionally
recapitulates differentiated human airway epithelial cells ex vivo
[28,29]. Based on our analysis, we propose that the HA mutations
would not be expected to mediate resistance of H5N1 viruses to
antiviral drugs, oseltamivir or zanamivir.
Results
Identification of HA Mutations that Alter the Receptor
Specificity of A/Vietnam/1203/04 (H5N1) Influenza Virus
To test the hypothesis that substitutions in the viral HA gene
can contribute to NA inhibitor resistance, we generated recom-
binant H5N1 viruses harboring HA point mutations that alter
viral receptor specificity or affinity to SA receptors, using two
approaches. Our group and others [11–18,30,31] had previously
identified a number of HA mutations within and near the receptor
binding site that could alter receptor specificity or affinity.
However, as a first step in this study, we wished to identify
additional HA point mutations that could convert the avian H5
HA to human-type receptor specificity. Previous studies had
shown that two HA substitutions (Q226L and G228S) are likely to
modulate receptor specificity in the H5 serotype [5]. We therefore
passaged the wild-type virus (rgVN1203) and two HA mutants
(Q226L and G228S) in MDCK-SIAT1 cells (Madin Darby canine
kidney cells altered to express predominantly human-type SAa2,6
receptors). Because of the ability of NA inhibitors to select mutants
with altered receptor affinity/specificity during in vitro passage, we
also cultured these three H5N1 viruses in MDCK-SIAT1 cells in
the presence of 1 mM oseltamivir [12–18]. Interestingly, infection
with the wild-type virus was undetectable by PCR analysis after
two passages with 1 mM of the NA inhibitor in two independent
experiments (data not shown). Sequence analysis of the entire HA
and NA genes revealed no additional mutations in virus with the
G228S substitution after five sequential passages in the presence or
absence of the drug. However, virus with the Q226L substitution
had acquired two additional HA mutations, N158S (which
eliminates a glycosylation site at position 158 [32]) and N248D,
after five passages with or without compound. The receptor
specificity of this triple-mutant (N158S/Q226L/N248D) virus was
determined by measuring its binding affinity to sialoglycopolymers
possessing either SAa2,3Gal (p39SL) or SAa2,6Gal (p69SL) (Table
S1). This H5N1 variant exhibited enhanced affinity for human-
like SAa2,6-linked receptor and was unable to bind the avian-like
SAa2,3-linked receptor (Figure S1); therefore, the N158S/
Q226L/N248D triple mutation is sufficient to completely switch
the host receptor specificity of A/Vietnam/1203/04 (H5N1) virus
from avian to human.
Characterization of Recombinant A/Vietnam/1203/04
(H5N1) Viruses with HA Mutations in or near the
Receptor Binding Site That Alter Receptor Specificity or
Affinity
Our second approach was to use reverse genetics [33] to
generate recombinant A/Vietnam/1203/04-like (H5N1) viruses
carrying HA mutations previously shown to alter receptor
specificity or affinity [11–18,30,31]. This study characterized a
total of 15 HA mutants (Table 1) carrying substitutions at a total of
11 positions (Figure 1A). In addition, to gain insight into how
combinations of HA and NA mutations can affect the sensitivity of
H5N1 virus to NA inhibitors, we rescued viruses carrying the 15
HA changes together with the H274Y NA substitution. This
mutation is most frequently associated with the resistance to the
NA inhibitor oseltamivir in the N1 NA subtype [11] and was
extensively characterized in A/Vietnam/1203/04 (H5N1)-virus
background both in vitro and in vivo [34] (Table S2).
The use of the eight-plasmid reverse genetics system allowed us
to predict the viability of all 31 recombinant H5N1 viruses in
nature. We were able to rescue all of the recombinant viruses from
transfected 293T cells as described previously [33]. However, the
introduced N158S, T160A, R229S, N158S/N248D, and Q226L/
N248D HA mutations could not be stably maintained in A/
Vietnam/1203/04 virus after one passage in MDCK cells in two
independent experiments because additional HA mutations were
observed (Table S2). Interestingly, A/Vietnam/1203/04 virus
simultaneously carrying the Q226L HA mutation and the H274Y
NA mutation was genetically unstable, since the stock virus
contained a mixture of viruses with Q or L at HA residue 226 as
well as a K222I HA substitution. Sequence analysis revealed that
the remaining 20 recombinant H5N1 viruses were stably
maintained in stock cultures; these viruses grew to comparable
titers in the different cell lines used (Table S2).
We measured the affinity of the 21 genetically stable
recombinant H5N1 variants, including wild-type virus, for a wide
range of high-molecular-weight sialic acid substrates, both natural
(fetuin) and synthetic (Table S1). Like most avian influenza strains,
wild-type rgVN1203 virus showed a binding preference for avian
SAa2,3Gal-receptors (Figure 1B). The introduced HA substitu-
tions had various effects on the receptor binding affinity of the H5
hemagglutinin to one or several SAa2,3Gal-substrates (Figure 1B).
Surprisingly, H5N1 mutants carrying the triple mutation N158S/
Q226L/N248D exhibited very weak SAa2,6Gal binding, whereas
virus with the double mutation N158S/Q226L did not bind to any
Author Summary
If the avian influenza H5N1 viruses adapt to human hosts,
the first step is likely to be a switch in the preference of
their viral hemagglutinin (HA) glycoprotein to bind to
human rather than avian cell receptors. Such a switch may
also alter virus susceptibility to neuraminidase (NA)
inhibitors, which are anti-influenza drugs that are likely
to be the first line of defense against a pandemic. We
generated recombinant A/Vietnam/1203/04-like (H5N1)
viruses carrying HA mutations previously shown to alter
receptor specificity or affinity. We also discovered a
previously unknown route (three simultaneous HA amino
acid substitutions) by which highly pathogenic H5N1
viruses can adapt to human receptors. We then used a
novel cell-culture–based system (differentiated human
airway epithelial NHBE cells) to evaluate the recombinant
viruses’ resistance to NA inhibitors. None of the HA-mutant
recombinants showed reduced drug susceptibility. Our
results indicate that the tested HA mutations are unlikely
to cause resistance to NA inhibitors in vivo. The NHBE
system meets the need for an appropriate cell-culture–
based system for phenotypic characterization of drug
resistance.
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SAa2,6Gal-substrate (Figure 1B).
After observing a discrepancy in the receptor affinity of two
N158S/Q226L/N248D HA triple mutants that were indepen-
dently obtained by passaging in MDCK-SIAT1 cells (Figure S1) or
by transfection of 293T-MDCK cells (Figure 1B), we investigated
whether the host cell type can determine viral binding properties.
We prepared virus stocks by transfecting MDCK-SIAT1 cells,
rather than MDCK cells, with the two H5N1 viruses carrying the
double N158S/Q226L and triple N158S/Q226L/N248D HA
substitutions. Direct sequencing of the double-mutant virus
revealed the presence of additional mutations; therefore, we did
not assay its receptor specificity. A/Vietnam/1203/04 (H5N1)
virus carrying the triple N158S/Q226L/N248D HA mutation
and grown in MDCK-SIAT1 cells was genetically stable and
demonstrated the switch from avian to human receptor specificity
(Figure 1B).
Susceptibility of the Recombinant H5N1 Viruses to NA
Inhibitors
We used the fluorometric NA enzyme inhibition assay [35] to
test the susceptibility to oseltamivir and zanamivir of the 20
recombinant H5N1 viruses carrying either HA mutations or both
HA and NA (H274Y) changes. None of the recombinants carrying
only HA mutations differed from the wild-type virus in their
sensitivity to either NA inhibitor (mean IC506SD, 0.260.1 and
1.060.1 nM, respectively, for oseltamivir and zanamivir). All
double-gene–mutant recombinant viruses were resistant to oselta-
mivir (the mean IC50 was ,2060 times that of wild-type virus) but
remained highly susceptible to zanamivir (IC50, 1.060.2 nM)
(data not shown).
We next compared the activity of NA inhibitors in four cell-
culture systems that differ in the surface distribution of SAa2,3-
and SAa2,6-receptors. We performed plaque reduction assays in
MDCK and MDCK-SIAT1 cells and virus reduction assays in
human alveolar basal epithelial (A549) and normal human
bronchial epithelial (NHBE) cells (Figures 2 and 3).
In MDCK cells, which express predominantly SAa2,3 (avian-
type) receptors [26], all HA mutants except those with the S159N
and N158S/Q226L substitutions were significantly more resistant
to oseltamivir and to zanamivir than the wild-type strain (P,0.01)
(Figure 2A). Introduction of the NA H274Y mutation markedly
reduced the sensitivity of the recombinant H5N1 viruses to
oseltamivir (mean EC50, 270 times that of the wild-type strain) but
did not alter their susceptibility to zanamivir. The combined HA
and NA (H274Y) substitutions therefore reduced oseltamivir
sensitivity synergistically in MDCK cells.
In MDCK-SIAT1 cells, which have predominantly SAa2,6
(human-type) receptors [26], most of the mutants showed
resistance to both NA inhibitors (Figure 2B), but fewer viruses
were resistant in MDCK-SIAT1 than in MDCK cells. Viruses
with Q226L, G228S and Q226L/G228S substitutions, which
Figure 1. (A) Crystal structure of the A/Vietnam/1203/04 hemagglutinin molecule (Protein Data Bank:2FK0) showing 11 positions in or near the
receptor binding site (yellow) at which amino acid substitutions can alter receptor specificity/affinity. Residues in red are positions where a single
substitution affects the stability of the H5N1 virus. (B) Affinity of recombinant A/Vietnam/1203/04-like (H5N1) influenza A viruses for high molecular
weight sialic acid substrates, both natural (fetuin) and synthetic. Of the nine substrates tested (Table S1), only the five shown here had a Kass
significantly different from that of the negative control. Bars represent the association constants (Kass) of virus in complex with sialylglycopolymer.
Values are the means6s.d. of four independent experiments.
doi:10.1371/journal.ppat.1000043.g001
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were as sensitive to both NA inhibitors as the wild-type virus in
MDCK-SIAT1 cells but not in MDCK cells (Figure 2). Taken
together, our results indicated that the drug sensitivity of the
recombinant H5N1 viruses detected in MDCK-SIAT1 cells
reflected their affinity for SAa2,6Gal rather than for SAa2,3Gal
receptors.
In human lung A549 cells, which have predominantly SAa2,6-
receptors [36], the overall sensitivity pattern was similar to that
observed in MDCK-SIAT1 cells (Figure 3A). However, we were
unable to assay the drug susceptibility of the mutants carrying the
double N158S/Q226L and triple N158S/Q226L/N248D HA
mutations, because their replication was undetectable. In A549
cells, but not in MDCK and MDCK-SIAT1 cells, only double
mutants with the Y161H or K222I HA substitution plus the
H274Y NA mutation showed resistance significantly greater (EC50
increased by a factor of 10-10
6) than that of the H274Y virus to
both NA inhibitors (Figure 3A).
In differentiated cultures of NHBE cells (primarily human-type
SAa2,6-receptors [28]), none of the HA mutations resulted in
increased resistance to oseltamivir or zanamivir, and there was no
difference in susceptibility between viruses carrying only the
H274Y NA mutation and those carrying HA mutations as well
(Figure 3B). Therefore, the combined HA–NA mutations had a
negligible effect on the NA inhibitor sensitivity of H5N1 viruses in
NHBE cultures. All recombinant viruses carrying a single HA
substitution were slightly less susceptible to zanamivir than to
oseltamivir (the EC50 differed by a factor of ,5) in NHBE cells.
This finding was consistent with the data obtained by NA enzyme
inhibition assay (see above).
Discussion
Our results answer several fundamental questions about the
effect of HA mutations on the host receptor affinity and NA
inhibitor susceptibility of highly pathogenic influenza H5N1
viruses. Importantly, we found that alteration of receptor
specificity or affinity does not alter sensitivity to NA inhibitors.
In light of global concern about pandemic preparedness, it is
crucial not only to understand what mutations might endow
H5N1 viruses with human receptor specificity [4–6] but also to
anticipate the clinical consequences of such adaptation. With
increasing clinical use and stockpiling of NA inhibitors for
pandemic preparedness, it is also crucial to elucidate molecular
mechanisms that contribute to drug resistance.
Mutations at specific positions (129/134, 182, 192, 227, and
226/228) in the HA gene of H5N1 influenza virus were recently
shown to reduce or eliminate binding affinity to avian-type
receptors and enhance affinity to human-type receptors
[5,6,37,38]. Here, we have identified another possible route of
adaptation to human receptors: simultaneous amino acid substi-
tutions at HA positions 158 (that results in the loss of a
glycosylation site), 226 and 248. Our study demonstrated the
importance not only of residues near or within the receptor
binding site, but also those structural elements that are located in
its vicinity that can affect host receptor specificity. H5N1 influenza
viruses in H5 clade 1, such as the virus used here, would be
Table 1. Hemagglutinin amino acid substitutions in A/Vietnam/1203/04-like (H5N1) recombinant viruses generated in this study
No. of HA amino acid substitutions Specific substitutions
a Location of substitutions in relation to receptor-binding site
One N158S form a N-linked glycosylation site at position 158, atop and to the
side of the receptor pocket
S159N
T160A
Y161H next to glycan at position 158 closed to the receptor pocket
H183N forms the rear of the site via a chain of hydrogen bonds linking
W153, Y195, Y98, and links via a water molecule to E190
K222I near the left edge of receptor pocket
Q226L form the left edge of receptor pocket
S227N
G228S
R229S next to the left edge of receptor pocket
Two N158S/Q226L N158 forms glycan closed to the site and Q226 forms the left edge of
the receptor pocket
N158S/N248D N158 forms glycan closed to the site and N248 is located in the
upper part of the HA globular head close to the edge of the receptor
pocket
Q226L/G228S form the left edge of receptor pocket
Q226L/N248D Q226 forms the left edge of the receptor pocket and N248 is located
in the upper part of the HA globular head
Three N158S/Q226L/N248D N158 forms glycan closed to the site; Q226 forms the left edge of the
receptor pocket; N248 is located in the upper part of the HA globular
head close to the edge of the receptor pocket
aAmino acid numbering is based on H3 HA (Nobusawa et al., 1991, Virology, 182, 475–485).
Note: Underlined HA mutations caused an unstable phenotype. The genetic stability of recombinant H5N1 viruses was monitored by plaque assay and by sequencing of
the HA and NA genes after transfection and after one passage in MDCK cells. Influenza virus was defined as genetically stable if it was able to replicate efficiently in the
cell line used, maintain a homogeneous plaque phenotype, and did not contain additional subpopulations based on the sequence analysis of the HA and NA genes
after one passage in MDCK cells. If different subpopulations were identified, those viruses were designated as unstable.
doi:10.1371/journal.ppat.1000043.t001
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members of the clade 2.2 family now circulating in Europe, the
Middle East and Africa already lack a glycosylation site at HA
position 158 [1]. This natural feature reduces the required
mutations to only two, thus enhancing the probability of such an
occurrence. Taken together, we can conclude that different amino
acid substitutions in the H5 HA enable to cause a shift from the
avian- to human-type specificity and along with the H5N1
evolution other strain-specific mutations cannot be excluded.
HA glycosylation has been reported to affect the specificity or
affinity of influenza viruses for cellular receptors [39–41]. Our
results directly demonstrate that HA glycosylation plays a role in
the viability of avian H5N1 influenza viruses in MDCK-SIAT1
cells, which express predominantly human-like SAa2,6Gal
receptors. We demonstrated that the loss of an MDCK-SIAT1
cell–synthesized oligosaccharide at position 158 of HA, adjacent to
the receptor binding site, increased the capacity of the virus to
bind to these cells. One possible explanation is that the removal of
an oligosaccharide attachment site from the tip of the HA1 subunit
eliminates steric hindrance that limits the accessibility of the
receptor pocket by this SA-containing oligosaccharide [41].
Further, our results confirm previous reports [39–41] that the
effect of oligosaccharide removal can differ with the host cell type
(MDCK vs. MDCK-SIAT1) in which the H5N1 virus is grown.
Therefore, the receptor affinity of the avian H5N1 influenza virus
may also be affected by the host cell–determined composition of
other oligosaccharides on the two H5 HA subunits.
Our results are consistent with what is known about the role of
the functional balance between the receptor-binding (HA) and
receptor-destroying (NA) activities of the surface glycoproteins in
efficient influenza virus infection [42,43]. The genetic and
phenotypic instability of 11 of our recombinant H5N1 viruses in
Figure 2. Susceptibility of recombinant A/Vietnam/1203/04-like (H5N1) influenza A viruses to NA inhibitors in (A) MDCK cells and
(B) MDCK-SIAT1 cells as determined by plaque reduction assay. EC50 was the dose of drug required to reduce plaque size by 50%. Values are
the means6s.d. of three independent experiments. * P,0.01 compared to wild-type rgVN1203 virus (one-way ANOVA performed for all viruses);
uP,0.01 compared to virus carrying only the NA H274Y substitution (one-way ANOVA performed for viruses carrying the H274Y NA mutation).
doi:10.1371/journal.ppat.1000043.g002
H5N1 Neuraminidase Inhibitor Resistance
PLoS Pathogens | www.plospathogens.org 5 April 2008 | Volume 4 | Issue 4 | e1000043vitro may reflect the functional mismatch of their HA and NA
glycoproteins. The balance between HA and NA functions could
also explain the diverse pattern of influenza virus susceptibility to
NA inhibitors observed in different cell-culture systems
[11,19,20,42,43]. The disparate HA–NA balance required to
infect MDCK, MDCK-SIAT1, and A549 cells, together with the
differences in SA receptors between these cell lines and human
respiratory epithelial cells, significantly limit the suitability of these
commonly used cell lines for phenotypic characterization of NA
inhibitor resistance.
NHBE cells cultured ex vivo [28,29,44] offer a new cell-culture–
based system that functionally and morphologically recapitulates
normal differentiated human airway epithelium; this system allows
improved evaluation of the NA inhibitor sensitivity of avian
influenza viruses that are potential human pathogens. Taken
together, our data demonstrate a parallel between virus suscep-
tibility determined by NA enzyme inhibition assay (which appears
to predict in vivo results [11,19,20]) and virus susceptibility in
NHBE cells (an ex vivo model). NHBE cells [28,44], which express
the sialic acid receptors present in humans, may offer an optimal
system for maintaining viral fitness and, as a consequence, for
prediction of influenza virus resistance to NA inhibitors in vivo. Our
results suggest that the HA mutations that alter the receptor
specificity or affinity of highly pathogenic H5N1 viruses are
unlikely to mediate concomitant resistance to NA inhibitors in vivo.
However, we cannot exclude the possibility that the HA
mutations might contribute to the selection of certain NA
mutations that lead to drug resistance simply by altering HA–
NA balance. Indeed, recent observation that H5N1 viruses from
clade 2 isolated in 2005 demonstrated a 25- to 30-fold decrease in
sensitivity to oseltamivir carboxylate compared with clade 1
viruses and none of the mutations known to confer NA inhibitor
resistance was observed [45], suggests that the decrease in
sensitivities may be due to drift mutations in the NA and HA
proteins. Additionally, our finding that A/Vietnam/1203/04 virus
carrying the Q226L HA mutation, which is known to switch the
receptor specificity in the H3 HA subtype [5], and the H274Y NA
mutation was not genetically stable, could provide evidence that
some HA mutations have the potential impact on the acquisition
of mutations in NA, including those that can lead to decreased
drug susceptibility. One, therefore, can speculate that the
identification of oseltamivir-resistant viruses as a significant
Figure 3. Susceptibility of recombinant A/Vietnam/1203/04-like (H5N1) influenza A viruses to NA inhibitors in (A) A549 and (B)
NHBE cells as determined by virus reduction assay. In A549 cells, EC50 was the dose of drug that reduced the TCID50 titer of culture
supernatant 50% as compared to no-drug controls 72 h after infection. In NHBE cells, virus yield was measured after 24 h incubation with 0, 0.1, 1, or
10 mM of NA inhibitor by TCID50 assay in MDCK cells. All concentrations yielded similar results; those obtained with 1 mM NA inhibitor are shown. *
P,0.01 compared to wild-type rgVN1203 virus, one-way ANOVA test performed for all viruses; uP,0.01 compared to H274Y virus, one-way ANOVA
test performed for viruses carrying the H274Y NA mutation.
doi:10.1371/journal.ppat.1000043.g003
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could be determined by preceding NA and/or HA mutations.
In conclusion, our findings can improve the monitoring of NA
inhibitor resistance among viruses with pandemic potential.
Further, sequence analysis of the NA gene alone, rather than
analysis of both the NA and HA genes, may adequately identify all
drug-resistant H5N1 variants. The human airway epithelial cell
cultures used in this study could also advance the study of drug
resistance mechanisms by serving as a suitable model of the human
respiratory cell system for phenotypic characterization of NA
inhibitor resistance in clinical testing.
Materials and Methods
Cells, viruses and compounds
Madin-Darby canine kidney (MDCK), human embryonic
kidney (293T) and human alveolar basal epithelial (A549) cells
were obtained from the American Type Culture Collection.
MDCK cells transfected with cDNA encoding human 2,6-
sialyltransferase (MDCK-SIAT1 cells) were kindly provided by
Dr. Mikhail N. Matrosovich. Primary normal human bronchial
epithelial (NHBE) cells were obtained from Cambrex Bio Science.
All cell cultures were maintained as previously described
[26,28,31,36,44].
Eight plasmids were constructed from the DNA sequences of
the 8 gene segments of wild-type A/Vietnam/1203/04 (H5N1)
virus for the reverse-genetics generation of recombinant wild-type
virus (rgVN1203). Recombinant virus was generated by DNA
transfection of 293T cells [33], the HA cleavage site was removed,
and the point mutations (Tables 1 and S2, Figure 1A) were
inserted into the HA and NA genes of rgVN1203 virus by using a
Quickchange site-directed mutagenesis kit (Stratagene) [32]. Stock
viruses were prepared in MDCK cells at 37uC for 72 h and their
entire HA and NA genes were sequenced to verify the presence of
the mutations. The recombinant viruses were designated accord-
ing to their HA and NA mutations (Tables 1 and S2). All
experimental work with the H5N1 recombinant viruses was
performed in a biosafety level 3+ laboratory approved for use by
the U.S. Department of Agriculture and the U.S. Centers for
Disease Control and Prevention.
The NA inhibitors oseltamivir carboxylate (oseltamivir)
([3R,4R,5S]-4-acetamido-5-amino-3-[1-ethylpropoxy]-1-cyclohex-
ene-1-carboxylic acid) and zanamivir (4-guanidino-Neu5Ac2en)
were provided by Hoffmann-La Roche, Ltd.
Cultivation of H5N1 influenza viruses in the presence or
absence of oseltamivir for identification of HA mutations
that alter receptor specificity
For the first passage, MDCK-SIAT1 cells were infected with
influenza H5N1 viruses at a multiplicity of infection (MOI) of
0.001 PFU/cell and cultivated for 72 h in infection medium
[containing 4% bovine serum albumin, sodium bicarbonate,
100 U/ml of penicillin, 100 mg/ml of streptomycin sulfate,
100 mg/ml of kanamycin sulfate, 1 mg/ml of L-1-(tosyl-amido-2-
phenyl)ethyl chloromethyl ketone (TPCK)–treated trypsin (trypsin)
(Worthington Diagnostics)] with or without 1 mM oseltamivir [31].
Four additional passages identical to the first one were then
performed sequentially.
Stability and infectivity of recombinant H5N1 viruses
The genetic stability of recombinant H5N1 viruses was
monitored by plaque assay and by sequencing of the HA and
NA genes after transfection of 293T cells and after one passage in
MDCK/MDCK-SIAT1 cells. Influenza virus was defined as
genetically stable if it was able to replicate efficiently in the cell
lines used, maintain a homogeneous plaque phenotype, and did
not contain additional subpopulations based on the sequence
analysis of the HA and NA genes after one passage in MDCK/
MDCK-SIAT1 cells. If different subpopulations were identified,
those viruses were designated as unstable (Tables 1 and S2).
The yield of H5N1 viruses in MDCK, MDCK-SIAT1 and
A549 cells was defined as log10 of the 50% tissue culture infectious
dose (TCID50) as described previously [43]. Briefly, confluent
monolayers of cell cultures growing in 96-well microplates were
inoculated with serial virus dilutions (each dilution was added to
five wells) in the presence of trypsin. After 3 days, virus was
titrated by HA assay, and virus titers were expressed as
log10TCID50/ml by the end-point method of Reed and Muench
[47]. NHBE cells were inoculated by exposure of the apical side to
recombinant H5N1 viruses at a MOI of 0.1, as determined by
TCID50 assay in MDCK cells. After 1 h incubation, the inoculum
was removed and the cells were incubated for 24 h. No trypsin was
added to the cultures because previous studies in similar cultures
demonstrated efficient proteolytic activation of influenza viruses by
endogenous proteases [28]. Viruses released into the apical
compartment of NHBE were harvested by adding 300 mlo f
medium to the apical compartment, allowing it to equilibrate for
30 min, and collecting it. Virus titer was determined as
log10TCID50/ml in MDCK cells.
Receptor-binding assay
The binding of human influenza viruses to fetuin was measured
in a direct solid-phase assay using the immobilized virus and
horseradish peroxidase-conjugated fetuin, as described previously
[48]. The affinity of viruses for synthetic 39- and 69-substrates
(Table S1) was measured in a competitive assay based on the
inhibition of binding of the labeled fetuin [49]. The association
constants (Kass) were determined as sialic acid (Neu5Ac) concen-
tration at the point Amax/2 on Scatchard plots.
NA enzyme inhibition assay
NA activity was determined as described by Potier et al. [35].
Briefly, H5N1 viruses and various concentrations of oseltamivir or
zanamivir were preincubated for 30 min at 37uC before addition
of the substrate 29-(4-methylumbelliferyl)-a-D-N-acetylneuraminic
acid (Sigma). After 1 h, the reaction was terminated by adding
14 mM NaOH and fluorescence was quantified in a Perkin-Elmer
fluorometer. The IC50 was defined as the concentration of NA
inhibitor necessary to reduce NA activity by 50% relative to that in
a reaction mixture containing virus but no inhibitor.
Drug susceptibility assays
The drug susceptibility of recombinant H5N1 viruses was
determined by plaque reduction assay in MDCK and MDCK-
SIAT1 cells [50] and by virus reduction assay in A549 and NHBE
cells [31,51]. Briefly, MDCK or MDCK-SIAT1 cells were
inoculated with virus diluted to yield ,50 plaques per well and
were then overlaid with infection medium containing oseltamivir
(0.0001 to 100 mM) or zanamivir (0.0001 to 100 mM) in the
presence of trypsin. The results were recorded after 3 days of
incubation at 37uC. At least three independent experiments were
performed to determine the concentration of compound required
to reduce plaque size by 50%, relative to that in untreated wells
(EC50).
A549 cells were inoculated with H5N1 viruses at an MOI of
0.001 PFU/cell and after 1 h of adsorption were overlaid with
infection medium containing oseltamivir (0.001 to 100 mM) or
zanamivir (0.001 to 100 mM) in the presence of trypsin. Virus yield
H5N1 Neuraminidase Inhibitor Resistance
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after inoculation. The drug concentration that caused a 50%
decrease in the TCID50 titer in comparison to control wells
without drug was defined as the 50% inhibitory concentration
(EC50). The results of three independent experiments were
averaged.
NHBE cells were inoculated by exposure of the apical side to
recombinant H5N1 viruses at an MOI of 0.1 in the presence of
oseltamivir (0, 0.1, 1, 10 mM) or zanamivir (0, 0.1, 1, or 10 mM).
These concentrations represent typical plasma minimum and
maximum concentrations measured in humans after administra-
tion of 75 mg of oseltamivir phosphate or 10 mg of zanamivir, the
doses recommended for prophylaxis [10,52]. After 1 h incubation,
the inoculum was removed and the cells were incubated for
another 24 h. Viruses released into the apical compartment of
NHBE cells were harvested by the apical addition and collection of
300 ml of medium allowed to equilibrate for 30 min. The virus
titer was determined as log10TCID50/ml in MDCK cells.
Supporting Information
Figure S1 Affinity of H5N1 variant with N158S/Q226L/
N248D triple mutation isolated after five passages in MDCK-
SIAT1 cells for sialyl substrates. Each data bar represents
association constant (Kass) of virus in complex with sialylglycopo-
lymer p39SL or p69SL (Table S1). Higher Kass values indicate
stronger binding. Values are the means6s.d. of four independent
experiments.
Found at: doi:10.1371/journal.ppat.1000043.s001 (0.13 MB TIF)
Table S1 Synthetic oligosaccharide-polyacrylamide substrates
used to test the receptor specificity of H5N1 viruses
Found at: doi:10.1371/journal.ppat.1000043.s002 (108 KB DOC)
Table S2 In vitro characterization of recombinant H5N1 viruses
Found at: doi:10.1371/journal.ppat.1000043.s003 (31.0 KB
DOC)
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